Illumina Shares Fall After Roche Launches Competing Gene Sequencer

Kaipu Biotech announced that its wholly owned subsidiary, Chaozhou Kaipu Biochemical Co., Ltd., has obtained a medical device registration certificate issued by the National Medical Products Administration. The approved product is a vaginal microbial nucleic acid detection kit, using PCR-fluorescent probe method, classified as a Class III in vitro diagnostic reagent. The product is used for qualitative detection of Trichomonas vaginalis, Gardnerella vaginalis, and Candida albicans nucleic acids in vaginal secretions.

Danaher announced in early October 2026 that it had launched its first AI-powered autonomous lab at Abcam, combining artificial intelligence, robotics and connected workflows to accelerate the design, building and testing of custom antibodies and other molecular tools. The lab's closed-loop system feeds every experimental result back into its AI models, a setup intended to lift both the speed and scale of reagent discovery while maintaining rigorous validation. The launch reinforces Danaher's Life Sciences automation and AI catalyst but does not materially change near-term sensitivities around bioprocessing demand or the risk that softer respiratory testing and China pricing could leave overall growth below what the market currently embeds. The announcement comes alongside the appointment of Julie Sawyer Montgomery as CEO from 1 October 2026, with execution on connected, automated workflows expected to depend heavily on leadership continuity and capital allocation discipline. Danaher's narrative projects $31.7 billion revenue and $6.1 billion earnings by 2029, requiring 8.1% yearly revenue growth and about a $2.1 billion earnings increase from $4.0 billion today, while three Simply Wall St Community fair value estimates cluster in a tight US$225.66 to US$239.86 range.

Danaher Corporation announced plans to launch its first AI-powered autonomous lab for antibody research, sending its shares up 2% in premarket trading Wednesday. The facility, expected to operate at scale in early 2027, will combine artificial intelligence, robotics and technologies from several Danaher operating companies to help researchers develop custom antibodies and other molecular tools, and is designed to deliver up to 8x faster discovery of affinity reagents and unlock up to a tenfold increase in annual reagent generation. Based at Abcam, a Danaher company, the lab uses AI to create new affinity reagents, including antibodies, then builds and tests each one, feeding results back into the model to improve subsequent designs, bringing together technologies from Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices in one connected workflow. Julie Sawyer Montgomery, President and Chief Executive Officer of Danaher, said the autonomous lab reflects the kind of progress Danaher is uniquely positioned to deliver, helping turn promising ideas into validated systems faster. The lab represents the first step in a broader Danaher initiative to create smart instruments, integrated workflows and autonomous labs that accelerate scientific research. Ahead of Wednesday's announcement, Barclays analyst Luke Sergott raised the price target on Danaher to $255.00 from $230.00 while maintaining an Overweight rating.

Roche Diagnostics has provided two molecular testing instruments to the Institut National de Santé Publique to support Ebola testing capacity in the Democratic Republic of Congo, where an outbreak caused by Bundibugyo virus has pushed demand for testing beyond current laboratory capacity. Roche will preconfigure the Light cycler and Magna Pure instruments and train local laboratory technicians before deploying the equipment to Bunia for validation testing. The Institut National de Santé Publique will conduct local validation of the Bundibugyo virus, after which Roche anticipates further tests could be shipped and additional instruments deployed. The delivery follows Roche's June announcement that it had developed a Research Use Only molecular PCR test targeting Bundibugyo virus. As of 28 September 2026, UN Health Authority data reported 8,067 confirmed cases and 3,901 deaths, a case fatality rate of 48.4% across 60 health zones in six provinces, and the WHO has assessed the risk in the DRC as very high and confirmed the outbreak remains a public health emergency of international concern.